MG-ZG122
/ Mabgeek
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 23, 2024
Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=34 | Active, not recruiting | Sponsor: Shanghai Mabgeek Biotech.Co.Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2023 ➔ Mar 2024 | Trial primary completion date: Aug 2023 ➔ Jan 2024
Enrollment closed • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
April 18, 2023
Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=34 | Recruiting | Sponsor: Shanghai Mabgeek Biotech.Co.Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • IL5
December 21, 2022
Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=34 | Not yet recruiting | Sponsor: Shanghai Mabgeek Biotech.Co.Ltd
New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • IL5
1 to 3
Of
3
Go to page
1